The Deep Dive: Fewer Episodes of Recurrence, So Why Expand This Heart Drug Trial? | Interview with David Elsley

Past Event Cardiol Therapeutics Phase III MAVERIC Trial. Why Fewer Recurrences Led to More PatientsOct 11, 2026

Past Event Ellis Martin Report: Cardiol Therapeutics CEO David Elsley: Phase III MAVERIC - What Comes Next $CRDLOct 08, 2026

Past Event Cardiol Therapeutics Fireside Chat at H.C. Wainwright's 28th Annual Global Investment ConferenceSep 14, 2026